Phase 3
N=437
Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
Diarrhea · Clostridium Infections
Bottom Line
View on ClinicalTrials.gov: NCT00328263 ↗Enrolled (actual)
437
Serious AEs
8.7%
Results posted
Aug 2014
Primary outcome: Primary: The Incidence of Antibiotic-associated Diarrhea. — 216; 221 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Lactobacillus acidophilus CL1285 and Lactobacillus casei (Dietary_supplement); placebo (Dietary_supplement)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Bio-K Plus International Inc.
- Primary completion
- Mar 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Incidence of Antibiotic-associated Diarrhea. |
216; 221 | — |
| SECONDARY Positive Results for Clostridium Difficile (C. Difficile) Toxin A or B in Antibiotic Associated Diarrhea Patients. |
— | — |
| SECONDARY Health Outcome Evaluation Will Look at the Direct Medical Costs and Clinical Outcomes of Alternative Strategies in the Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients |
— | — |
| SECONDARY Safety Profile of BIO-K+CL1285® Versus Placebo in Patients on Antibiotics |
— | — |
Summary
The purpose of this study is to evaluate the efficacy and safety of Bio-K + CL1285 versus placebo in the prevention of antibiotic-associated diarrhea in hospitalized adult patients.
Eligibility Criteria
Inclusion Criteria
- presenting to the Emergency Room and considered for admission to hospital for a minimum of 12 hours and requiring antibiotic administration for the treatment of a suspected or proven bacterial infection OR a hospitalized patient developing a suspected or proven nosocomial infection OR an external patient that come to the hospital for repeated visits to receive his intravenous antibiotic therapy for the treatment of a suspected or proven bacterial infection. The external patients on oral antibiotics that come to the hospital for repeated visits to receive any other treatments requiring a hospital stay of more than one hour will also be included.
- Hospital employee on antibiotics can also be included in the study
- having received less than 24 hours of antibiotic therapy;
- requiring a minimum of 3 days and a maximum of 14 days antibiotic administration
Informed consent must be obtained in writing for all subjects at enrollment into the study
Exclusion Criteria
Subjects presenting with any of the following will not be included in the study:
- active diarrhea;
- a history of daily consumption of fermented milk and/or yogurt;
- intolerance to lactose;
- pregnant/breastfeeding women;
- an active, non controlled intestinal disease such as Crohn's Disease or ulcerative colitis;
- ileostomy, jejunostomy or colostomy;
- immunosuppressed state;
- a previous documented C. difficile infection in the three months prior to study initiation;
- active radiotherapy or chemotherapy;
- recent (< 6 months) or planned bone marrow graft or organ transplant;
- antibiotic therapy in the fourteen days prior to study initiation;
- the planned administration of metronidazole (alone or in combination) or vancomycin monotherapy for the treatment of an infection;
- mental or other conditions, or language barriers rendering the subject unable to understand the nature, scope, and possible consequences of the study or complete the self-administered questionnaires;
- subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.
Post-enrollment exclusion criteria include fermented milk and/or yogurt consumption during the study period and two consecutive missed dose of study product.
Data sourced from ClinicalTrials.gov (NCT00328263). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.